FDA approves Jazz's Ziihera in frontline gastric cancer
Jazz Pharmaceuticals’ bispecific antibody Ziihera won a label expansion to treat certain patients with gastric cancer. It’s the first time Ziihera will be marketed to newly diagnosed patients, following its 2024 approval for certain patients ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma financialpost.com
- Jazz wins FDA nod for cancer therapy developed with BeOne, Zymeworks seekingalpha.com
- FDA approves Tevimbra combo for HER2+ gastric cancer treatment investing.com
